TargetMol

Olmesartan

Product Code:
 
TAR-T5964
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5964-25mg25mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5964-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5964-50mg50mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5964-100mg100mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5964-500mg500mg£293.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Olmesartan is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.
CAS:
144689-24-7
Formula:
C24H26N6O3
Molecular Weight:
446.511
Pathway:
Endocrinology/Hormones
Purity:
0.9903
SMILES:
CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1)C(C)(C)O
Target:
RAAS

References

Omboni S, Volpe M.Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan[1].Cardiovasc Ther. 2018 Dec;36(6):e12471. Haller H , Ito S , Izzo J L , et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes[J]. New England Journal of Medicine, 2011, 364(10):907-917.